Oxygen Biotherapeutics, Inc. Share Price Nasdaq
Equities
US69207P2092
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 6.13M 512M |
---|---|---|---|---|---|
Net income 2024 * | -19M -1.59B | Net income 2025 * | -18M -1.5B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.38
x | P/E ratio 2025 * |
-0.84
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.65% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 14/21/14 | |
Director of Finance/CFO | 69 | 11/01 | |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 15/21/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerry Proehl
CHM | Chairman | 65 | 04/14/04 |
June Almenoff
BRD | Director/Board Member | 67 | 25/21/25 |
Declan Doogan
BRD | Director/Board Member | 72 | 25/21/25 |
1st Jan change | Capi. | |
---|---|---|
+23.13% | 52.73B | |
+37.49% | 39B | |
-8.73% | 38.52B | |
+28.09% | 30.38B | |
-12.26% | 26.39B | |
+10.57% | 26.08B | |
+45.05% | 14.15B | |
+32.23% | 12.6B | |
-6.56% | 11.51B |